FDA Fast-Tracks Nelkarmi for Lung Cancers That Outsmarted Earlier Drugs
The FDA granted accelerated approval to Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer already treated with other ALK-targeted drugs. The once-daily pill shrank tumors in 49% of patients who had progressed on alectinib, giving a shrinking group of options a new one.
- Original source: curetoday.com.
- The source published it on Nov 17, 2026 at 10:11 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA handed accelerated approval to Nelkarmi (neladalkib) on Nov. 17, clearing the once-daily pill for adults whose locally advanced or metastatic ALK-positive non-small cell lung cancer has already been treated with other ALK-targeted drugs. The green light covers patients whose disease can't be removed by surgery and who previously took either alectinib (Alecensa) or at least two ALK tyrosine kinase inhibitors plus platinum-based chemotherapy. Nelkarmi works by blocking the ALK protein that fuels the growth of these tumors.
The approval rests on ALKOVE-1, a single-arm trial in which every patient received Nelkarmi. Among 67 patients who had been treated with alectinib, tumors shrank in 49%; of those responders, 76% held that response for at least six months and 52% for at least a year. In the 155 patients who had already cycled through two or more ALK inhibitors and platinum-based chemotherapy, tumors shrank in 32%, with 69% of responders lasting at least six months and 51% at least a year.
That matters because ALK-positive lung cancers often quit responding to earlier ALK inhibitors as new mutations take hold, whittling down targeted choices. The FDA's accelerated pathway lets serious conditions get drugs based on early signs of benefit like tumor shrinkage, with continued approval potentially hinging on a confirmatory trial. The application got priority review, and neladalkib arrived with breakthrough therapy and orphan drug designations attached.
The label carries a hefty side-effect list. At least 20% of patients hit liver problems, muscle and bone pain, constipation, taste changes, peripheral neuropathy that can cause numbness or tingling, edema and fatigue. Prescribing information also flags liver damage, kidney problems, eye problems, rising creatine phosphokinase — an enzyme that can signal muscle damage — and possible harm to a developing baby. Patients are told to report vision changes, unexplained muscle pain or weakness, or liver-trouble signs like yellowing skin or dark urine, and to discuss birth control during treatment.
The recommended dose is 150 mg by mouth once a day, with or without food, at roughly the same time each day. Treatment runs until the cancer grows or the side effects become too much to handle.
TopicsNelkarmi · neladalkib · FDA · ALKOVE-1 · alectinib · Alecensa · ALK-positive non-small cell lung cancer · tyrosine kinase inhibitors
Source: curetoday.com
Written by AI from verified reporting.
More stories
- Health & science yahoo.com 0 viewsFDA clears GSK lung cancer drug for advanced cases
- Health & science techtimes.com 0 viewsPierre Fabre's lung cancer pill wins FDA fast track with no data public
- Health & science apnews.com 0 viewsUS and Mexico stripped of measles-free status, international health officials say
- Health & science cbsnews.com 0 viewsChina fires scientist after girl, 6, died in hidden gene-editing trial

